Actinium Pharmaceuticals (ATNM) Stock: Buy, Sell, or Hold?
ATNM - Actinium Pharmaceuticals, Inc
$1.03
-0.02 (-1.90%)
âŧ
5d:
+1.98%
30d:
+30.88%
90d:
-4.63%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When ATNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ATNM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ATNM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: ATNM is currently trading at $1.03, which is considered slightly high relative to its 30-day fair value range of $0.83 to $1.08.
Technical Outlook: Technically, ATNM is in a downtrend. Immediate support is located at $0.97, while resistance sits at $1.10.
Market Sentiment: ATNM scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.50 (+239.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATNM is in a downtrend. Immediate support is located at $0.97, while resistance sits at $1.10.
Market Sentiment: ATNM scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.50 (+239.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.83 -
$1.08
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
42.1%
All Signals
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 239.8% below Wall St target ($3.50)
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.83 -
$1.08
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.97
Resistance Level
$1.10
Current Trend
Downtrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.96
Wall Street Target
$3.50
(+239.8%)
Revenue Growth (YoY)
-100.0%
Profit Margin
32.2%
Share & Embed Analysis
Last updated: September 07, 2026 9:05 AM ET
Data refreshes hourly during market hours. Next update: 10:05 AM
Data refreshes hourly during market hours. Next update: 10:05 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATNM showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 46 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 26 SELL |
|
VRTX
Vertex Pharmaceuticals IâĻ |
BUY
34 analysts |
$570 | 40 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$59 | 64 BUY |
|
APLS
Apellis Pharmaceuticals âĻ |
BUY
22 analysts |
$41 | 50 HOLD |
